Haihe Pharmaceutical: Signed exclusive product license and strategic cooperation agreement with Aixinda Wei.

Haizheng Pharmaceutical announced that the company has signed a product exclusive license and strategic cooperation agreement with Shenzhen Aixinda Wei Pharmaceutical Technology Co., Ltd. The company plans to introduce the global first-in-class small molecule prodrug AST-3424 developed by Aixinda Wei in the cooperation area, and will pay an initial payment to Aixinda Wei. The company will also pay development milestone payments to Aixinda Wei based on the actual achievement of development milestones, with a total cost not exceeding 240 million yuan. At the same time, the company will carry out strategic cooperation with Aixinda Wei in the development of the AKR1C3 enzyme activation platform.